Steatotic Liver Disease Clinical Trials

67 recruitingLast updated: July 25, 2026

There are 67 actively recruiting steatotic liver disease clinical trials across 46 countries. Studies span Not Applicable, Phase 2, Phase 1, Early Phase 1, Phase 3, Phase 4. Top locations include Barcelona, Spain, La Jolla, California, United States, San Antonio, Texas, United States. Updated daily from ClinicalTrials.gov.


Steatotic Liver Disease Trials at a Glance

67 actively recruiting trials for steatotic liver disease are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Not Applicable with 25 trials, with the heaviest enrollment activity in Barcelona, La Jolla, and San Antonio. Lead sponsors running steatotic liver disease studies include Regeneron Pharmaceuticals, Hospices Civils de Lyon, and Corcept Therapeutics.

Browse steatotic liver disease trials by phase

Treatments under study

About Steatotic Liver Disease Clinical Trials

Looking for clinical trials for Steatotic Liver Disease? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Steatotic Liver Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Steatotic Liver Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 67 trials

Recruiting

A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

Metabolic Dysfunction-Associated Steatotic Liver DiseasePlaque Psoriasis
Novartis Pharmaceuticals150 enrolled3 locationsNCT07683065
Recruiting
Phase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled563 locationsNCT07165028
Recruiting
Phase 2

Effect of Ketone Esters on Liver Fat Content and Metabolic Function

ObesityOverweight (BMI > 25)MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Washington University School of Medicine40 enrolled1 locationNCT07097506
Recruiting
Not Applicable

Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease

Metabolic Dysfunction-Associated Steatotic Liver Disease
Cliniques universitaires Saint-Luc- Université Catholique de Louvain60 enrolled2 locationsNCT06506513
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled361 locationsNCT06318169
Recruiting
Phase 1Phase 2

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
Regeneron Pharmaceuticals132 enrolled4 locationsNCT06836609
Recruiting
Not Applicable

Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD

Obesity, OverweightMetabolic Dysfunction-Associated Steatotic Liver DiseaseNon-alcoholic Fatty Liver Disease NAFLD+1 more
Taipei Medical University60 enrolled1 locationNCT07692438
Recruiting
Not Applicable

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

Non alcoholic steato hepatitis (NASH)Liver Fibrosis/NASHMetabolic dysfunction–associated steatotic liver disease (MASLD)
Université de Sherbrooke36 enrolled1 locationNCT06843148
Recruiting
Not Applicable

Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Nantes University Hospital72 enrolled9 locationsNCT07378072
Recruiting
Not Applicable

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Insulin Sensitivity/ResistanceObesityInsulin Resistance+16 more
Pichamol Jirapinyo, MD, MPH132 enrolled2 locationsNCT06138821
Recruiting
Phase 2

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Metabolic dysfunction–associated steatotic liver disease (MASLD)
Regeneron Pharmaceuticals204 enrolled5 locationsNCT07527910
Recruiting
Not Applicable

UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla450 enrolled3 locationsNCT07652151
Recruiting
Not Applicable

Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD

Metabolic dysfunction-associated steatohepatitis (MASH)MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Hospices Civils de Lyon24 enrolled1 locationNCT07313007
Recruiting

Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme

ObesityLiver FibrosisMetabolic Dysfunction-Associated Steatotic Liver Disease+3 more
Hospital General Universitario Gregorio Marañon3,000 enrolled1 locationNCT07658755
Recruiting
Phase 2

SMART Diets for MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease
Michigan State University102 enrolled1 locationNCT07459504
Recruiting
Phase 1

Evaluating the Pharmacokinetics and Safety of Miricorilant

Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Not Applicable

EVOO and Metabolic Liver Health in MASLD

OverweightMASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis60 enrolled1 locationNCT07412444
Recruiting
Phase 2

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

HIV (Human Immunodeficiency Virus)MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Naga P. Chalasani120 enrolled10 locationsNCT07143968
Recruiting
Phase 2

Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial

MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseFatty Liver Disease, NonalcoholicOverweight (BMI > 25)
AB Biotics, SA60 enrolled1 locationNCT07193927
Recruiting
Not Applicable

Rehabilitation With Exercise-Based Intervention for Nonalcoholic Chronic Hepatic Esteatosis

Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)Metabolic Adaptation to High-Intensity Interval Training
Universidad San Sebastián30 enrolled1 locationNCT07552727